ASX:AC8 - Auscann Group Stock Price, News & Analysis

Today's Range N/A
50-Day Range
A$0.36
MA: A$0.41
A$0.52
52-Week Range N/A
Volume464,456 shs
Average VolumeN/A
Market Capitalization$114.40 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
AusCann Group Holdings Ltd researches, develops, cultivates, produces, and sells clinically validated cannabis medicines to patients in Australia. The company has a strategic partnership with Tasmanian Alkaloids. AusCann Group Holdings Ltd is headquartered in Joondalup, Australia.

Industry, Sector and Symbol

Industry Drug Manufacturers - Specialty & Generic
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone61 0 9561 8834

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$670,606.00
Book ValueA$0.13 per share

Profitability

Miscellaneous

EmployeesN/A
Market Cap$114.40 million
Next Earnings DateN/A
OptionableNot Optionable

Receive AC8 News and Ratings via Email

Sign-up to receive the latest news and ratings for AC8 and its competitors with MarketBeat's FREE daily newsletter.


Auscann Group (ASX:AC8) Frequently Asked Questions

What is Auscann Group's stock symbol?

Auscann Group trades on the ASX under the ticker symbol "AC8."

Has Auscann Group been receiving favorable news coverage?

Headlines about AC8 stock have trended negative this week, InfoTrie reports. The research firm scores the sentiment of press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Auscann Group earned a news impact score of -2.9 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the stock's share price in the immediate future. View News Stories for Auscann Group.

Who are some of Auscann Group's key competitors?

What other stocks do shareholders of Auscann Group own?

Who are Auscann Group's key executives?

Auscann Group's management team includes the folowing people:
  • Dr. Paul Donald Richard MacLeman MBA, BVSc, Grad Dip Tech, Grad Cert Eng, GAICD, MA, Interim CEO & Exec. Director (Age 53)
  • Mr. Quentin Heath Megson, Chief Operating & Financial Officer and Joint Company Sec. (Age 48)
  • Ms. Susan Patricia Hunter A.C.A., B.Com., BCom, F Fin, ACA, AGIA, FFin, GAIC, Company Sec. (Age 44)
  • Dr. Danial Schecter, Chief Medical Advisor (Age 45)

How big of a company is Auscann Group?

Auscann Group has a market capitalization of $0.00 and generates $670,606.00 in revenue each year. View Additional Information About Auscann Group.

What is Auscann Group's official website?

The official website for Auscann Group is http://www.auscann.com.au/.

How can I contact Auscann Group?

The company can be reached via phone at 61 0 9561 8834.


MarketBeat Community Rating for Auscann Group (ASX AC8)

Community Ranking:  1.5 out of 5 (star half star)
Outperform Votes:  3 (Vote Outperform)
Underperform Votes:  7 (Vote Underperform)
Total Votes:  10
MarketBeat's community ratings are surveys of what our community members think about Auscann Group and other stocks. Vote "Outperform" if you believe AC8 will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AC8 will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 9/19/2019 by MarketBeat.com Staff

Featured Article: Stock Portfolio Tracker

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel